Metabotropic glutamate receptor II in the brains of parkinsonian patients

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 4, 2009, Pages 374-382

  Samadi, Pershia ^a   Rajput, Alex ^b   Calon, Frédéric ^a   Grégoire, Laurent ^a   Hornykiewicz, Oleh ^b,c   Rajput, Ali H ^b   Di Paolo, Thèrèse ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dyskinesias; MGluR2 3; Parkinson disease; Wearingoff

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; LEVODOPA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; RADIOLIGAND; SELEGILINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; AMINO ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; COCAINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; METABOTROPIC RECEPTOR; RADIOACTIVE IODINE; TRITIUM; XANTHENE DERIVATIVE;

AGED; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN LEVEL; BRAIN SLICE; CADAVER; CAUDATE NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; DRUG TREATMENT FAILURE; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; TREATMENT RESPONSE; BRAIN; DRUG EFFECT; METABOLISM; PARKINSONISM; PATHOLOGY; RADIOASSAY;

AGED; AGED, 80 AND OVER; AMINO ACIDS; ANTIPARKINSON AGENTS; BRAIN; COCAINE; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEVODOPA; MALE; PARKINSONIAN DISORDERS; POSTMORTEM CHANGES; RADIOLIGAND ASSAY; RECEPTORS, METABOTROPIC GLUTAMATE; TRITIUM; XANTHENES;

EID: 65349101603     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31819cabe4     Document Type: Article

References (56)

1. Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol 2003;91:9-18
2. Mercuri NB, Bernardi G. The 'magic' of L-Dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 2003;26:341-344
3. Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: A 9-question survey assessment. Clin Neuropharmacol 2006;29: 312-321
4. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-1938
5. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508
6. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003;14: 404-16
7. Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000;23: S57-S63
8. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le Goff L, Salin P. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: Effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 2006;24: 1802-1814
9. Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids 2002;23:185-191
10. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6: 787-98
11. Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res 2006;326:483-504
12. Richards G, Messer J, Malherbe P, et al. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: Correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding. J Comp Neurol 2005;487:15-27
13. Pisani A, Bonsi P, Catania MV, et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci 2002;22:6176-85
14. Phillips T, Rees S, Augood S, et al. Localization of metabotropic glutamate receptor type 2 in the human brain. Neuroscience 2000;95:1139-1156
15. Smith Y, Charara A, Paquet M, et al. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia. J Chem Neuroanat 2001;22:13-42
16. Testa CM, Friberg IK, Weiss SW, Standaert DG. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J Comp Neurol 1998;390:5-19
17. Bradley SR, Marino MJ, Wittmann M, et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 2000;20:3085-3094
18. Mudo G, Trovato-Salinaro A, Caniglia G, Cheng Q, Condorelli DF. Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain. Brain Res 2007;1149:1-13
19. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 2001;106: 481-503
20. Morishima Y, Miyakawa T, Furuyashiki T, Tanaka Y, Mizuma H, Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc Natl Acad Sci U S A 2005;102:4170-4175
21. David HN, Abraini JH. Differential modulation of the D1-like and D2-like dopamine receptor-induced locomotor responses by group II metabotropic glutamate receptors in the rat nucleus accumbens. Neuropharmacology 2001;41:454-463
22. Dawson L, Chadha A, Megalou M, Duty S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 2000;129:541-546
23. Ossowska K, Konieczny J, Wardas J, et al. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 2007;32: 179-188
24. Feeley Kearney JA, Albin RL. mGluRs: A target for pharmacotherapy in Parkinson disease. Exp Neurol 2003;184(Suppl 1):S30-S36
25. Picconi B, Pisani A, Centonze D, et al. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 2002;125:2635-2645
26. Messenger MJ, Dawson LG, Duty S. Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract. Neuropharmacology 2002;43: 261-271
27. Samadi P, Gregoire L, Morissette M, et al. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-DopaYinduced dyskinesias. Neuropharmacology 2008;54:258-268
28. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127:1075-1084
29. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003;18:241-253
30. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002;61:186-196
31. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-296
32. Kingsbury AE, Foster OJ, Nisbet AP, et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995;28:311-318
33. Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 2001;298:453-460
34. Mai JK, Assheuer J, Paxinos G. Atlas of the Human Brain. San Diego, CA: Academic Press, 1997:193
35. Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord 2004;10:221-226
36. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49:298-303
37. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330
38. Nadjar A, Brotchie JM, Guigoni C, et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: A call for a reappraisal of the functional organization of the basal ganglia. J Neurosci 2006;26:8653-8661
39. Bonsi P, Cuomo D, Picconi B, et al. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 2007;32:189-195
40. Mela F, Marti M, Fiorentini C, Missale C, Morari M. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Mol Cell Neurosci 2006;31:284-292
41. Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA. The role of dopamine in cognitive sequence learning: Evidence from Parkinson's disease. Behav Brain Res 2005;156:191-199 (Pubitemid 39576059)
42. Seger CA, Cincotta CM. The roles of the caudate nucleus in human classification learning. J Neurosci 2005;25:2941-51
43. Grabli D, McCairn K, Hirsch EC, et al. Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study. Brain 2004;127:2039-2054 (Pubitemid 39150262)
44. Higgins GA, Ballard TM, Kew JN, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004;46:907-917
45. Levesque M, Parent A. The striatofugal fiber system in primates: A reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci U S A 2005;102:11888-11893
46. Poisik O, Raju DV, Verreault M, et al. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 2005;49(Suppl 1):57-69
47. Cho K, Bashir ZI. Cooperation between mGlu receptors: A depressing mechanism? Trends Neurosci 2002;25:405-411
48. Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinsonism. J Neurosci 2006;26: 8101-8114
49. O'Neill MF, Heron-Maxwell C, Conway MW, Monn JA, Ornstein P. Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 2003;45:565-574
50. Moldrich RX, Aprico K, Diwakarla S, O'Shea RD, Beart PM. Astrocyte mGlu(2/3)-mediated cAMP potentiation is calcium sensitive: Studies in murine neuronal and astrocyte cultures. Neuropharmacology 2002;43: 189-203
51. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677
52. Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003;61:S107-S111
53. Ohishi H, Neki A, Mizuno N. Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: An immunohistochemical study with a monoclonal antibody. Neurosci Res 1998;30:65-82 (Pubitemid 28119150)
54. Hauser RA. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. Geriatrics 2006;61:14-20
55. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910
56. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: Pharmacokinetic considerations. Expert Opin Pharmacother 2006;7: 1399-1407